VERFAHREN ZUR HERSTELLUNG VON TRIAZOLDERIVATEN

Triazole derivs. of formula (I) and their salts are new: (R1 and R2 are each H, NO2, alkyl, alkoxy, alkoxyalkyl or halo. R3 = H, alkyl, halo, alkoxy or NO2. n = 1 or 2). They are prepd. e.g. by reacting the appropriate benzaldehyde with 3-hydrazino-1,2,4-triazole. (I) have hypotensive activity and a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	BERNTSSON,PEDER B.,SE, GAARDER,JAN OE.,SE, LJUNG,BENGT R.,SE
Format:	Patent
Sprache:	ger
Schlagworte:	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Triazole derivs. of formula (I) and their salts are new: (R1 and R2 are each H, NO2, alkyl, alkoxy, alkoxyalkyl or halo. R3 = H, alkyl, halo, alkoxy or NO2. n = 1 or 2). They are prepd. e.g. by reacting the appropriate benzaldehyde with 3-hydrazino-1,2,4-triazole. (I) have hypotensive activity and are free from sedative or other side-effects. The usual dose is 0.1-1 g./day orally or 5-40 mg./day intravenously. A specifically claimed cpd. is 3-(2,6-dimethylbenzylidenehydrazino)-1,2,4-triazole.